September 14, 2020 – Rennova Health, Inc. (OTC: RNVA) (OTC: RNVAW), today announced that it has purchased and taken delivery of equipment to provide rapid testing for Coronavirus Disease 2019 (COVID-19) at three sites, two of its hospitals in East Tennessee and its rural clinic in Kentucky.
Rennova entered an agreement with Abbott laboratories to install and provide the ID NOW testing to our facilities. ID NOW provides results in 15 minutes utilizing state of the art molecular techniques (isothermal amplification of viral RNA). This test is approved under U.S. Food and Drug Administration Emergency Use Authorization (EUA) from direct nasal or noso-pharyngeal swabs. Testing is expected to begin in September at all 3 facilities. Patients may come to the facilities at their own wish or with a doctor’s order for the testing and leave with a result.
“It has become apparent that for diagnosing and managing COVID-19, laboratory testing should provide rapid and sensitive results on a same-day, current status of an individual regarding infection by the SARS-CoV-2” said Seamus Lagan, CEO of Rennova Health, Inc. “Particularly in acute settings such as emergency rooms, primary care visits, and surgery a fast result is necessary. We believe this investment in a FDA approved COVID-19 rapid test offers an excellent solution that can be used by our patients and the community and offered to a broader population in coming months”
About Rennova Health, Inc.
Rennova owns three rural hospitals and a physician’s office in Tennessee and a rural clinic in Kentucky, and provides industry-leading diagnostics and supportive software solutions to healthcare providers. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com
